Biodexa Pharmaceuticals Plc (BDRX)
NASDAQ: BDRX · Real-Time Price · USD
0.6910
+0.0309 (4.68%)
At close: Mar 25, 2026, 4:00 PM EDT
0.7095
+0.0185 (2.68%)
Pre-market: Mar 26, 2026, 4:01 AM EDT
Biodexa Pharmaceuticals Employees
Biodexa Pharmaceuticals had 13 employees as of December 31, 2024. The number of employees decreased by 8 or -38.10% compared to the previous year.
Employees
13
Change (1Y)
-8
Growth (1Y)
-38.10%
Revenue / Employee
n/a
Profits / Employee
-$656,254
Market Cap
4.28M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 13 | -8 | -38.10% |
| Dec 31, 2023 | 21 | -6 | -22.22% |
| Dec 31, 2022 | 27 | 7 | 35.00% |
| Dec 31, 2021 | 20 | 2 | 11.11% |
| Dec 31, 2020 | 18 | -47 | -72.31% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Aptevo Therapeutics | 37 |
| VivoSim Labs | 14 |
| Genprex | 13 |
| Azitra | 12 |
| Revelation Biosciences | 9 |
| Purple Biotech | 9 |
| Artelo Biosciences | 7 |
| Indaptus Therapeutics | 7 |
BDRX News
- 2 days ago - Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group - GlobeNewsWire
- 7 days ago - ADR Ratio Change - GlobeNewsWire
- 16 days ago - Biodexa Announces Support for Life's a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients - GlobeNewsWire
- 4 weeks ago - Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer - Accesswire
- 7 weeks ago - Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST - GlobeNewsWire
- 2 months ago - Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary - GlobeNewsWire
- 3 months ago - Biodexa Announces Pricing of $10 Million Public Offering - GlobeNewsWire
- 4 months ago - Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP - GlobeNewsWire